Literature DB >> 1664985

X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

D T Purtilo1.   

Abstract

Entities:  

Mesh：

Year:  1991        PMID： 1664985     DOI： 10.1007/bf00201468

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  66 in total

1.  The Epstein-Barr virus and neoplasia.

Authors:  G Klein
Journal:  N Engl J Med       Date:  1975-12-25       Impact factor: 91.245

2.  Expression of Epstein-Barr virus-encoded proteins and B-cell markers in fatal infectious mononucleosis.

Authors:  K Falk; I Ernberg; R Sakthivel; J Davis; B Christensson; J Luka; M Okano; H L Grierson; G Klein; D T Purtilo
Journal:  Int J Cancer       Date:  1990-12-15       Impact factor: 7.396

3.  Immunodeficiency to the Epstein-Barr virus in the X-linked recessive lymphoproliferative syndrome.

Authors:  D T Purtilo; L Hutt; J Bhawan; J P Yang; C Cassel; S Allegra; F S Rosen
Journal:  Clin Immunol Immunopathol       Date:  1978-02

Review 4.  The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990.

Authors:  D T Purtilo; H L Grierson; J R Davis; M Okano
Journal:  Pediatr Pathol       Date:  1991 Sep-Oct

5.  Methods of detection of new families with X-linked lymphoproliferative disease.

Authors:  D T Purtilo; H L Grierson
Journal:  Cancer Genet Cytogenet       Date:  1991-02

6.  Suppression of hematopoiesis by activated T-cells in infectious mononucleosis associated with pancytopenia.

Authors:  Y Iishi; M Kosaka; T Mizuguchi; K Toyota; Y Takaue; Y Kawano; S Saito
Journal:  Int J Hematol       Date:  1991-02       Impact factor: 2.490

7.  Hepatitis in fatal infectious mononucleosis.

Authors:  R S Markin; J Linder; K Zuerlein; E Mroczek; H L Grierson; B Brichacek; D T Purtilo
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

8.  Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry.

Authors:  D T Purtilo; K Sakamoto; V Barnabei; J Seeley; T Bechtold; G Rogers; J Yetz; S Harada
Journal:  Am J Med       Date:  1982-07       Impact factor: 4.965

9.  Delayed onset of infectious mononucleosis associated with acquired agammaglobulinemia and red cell aplasia.

Authors:  D T Purtilo; L Zelkowitz; S Harada; C D Brooks; T Bechtold; H Lipscomb; J Yetz; G Rogers
Journal:  Ann Intern Med       Date:  1984-08       Impact factor: 25.391

10.  Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients.

Authors:  D T Purtilo
Journal:  AIDS Res       Date:  1986-12
View more
  5 in total

1.  DSHP: a "power bar" for sustained immune responses?

Authors:  A B Satterthwaite; D J Rawlings; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

Review 2.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

3.  Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.

Authors:  Sajal K Ghosh; Susan P Perrine; Douglas V Faller
Journal:  Adv Virol       Date:  2012-03-05

4.  NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus.

Authors:  Olivia Hatton; Dara Marie Strauss-Albee; Nancy Q Zhao; Mikel D Haggadone; Judith Shanika Pelpola; Sheri M Krams; Olivia M Martinez; Catherine A Blish
Journal:  Front Immunol       Date:  2016-12-15       Impact factor: 7.561

5.  Case Report: Meningoencephalitis With Thrombotic Occlusive Vasculopathy in a Young EBV-Naïve Boy Is Associated With a Novel SH2D1A Mutation.

Authors:  Jolanda Steininger; Raphael Rossmanith; Christoph B Geier; Alexander Leiss-Piller; Lukas Thonhauser; Simone Weiss; Johannes A Hainfellner; Michael Freilinger; Wolfgang M Schmidt; Martha M Eibl; Hermann M Wolf
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.